| Literature DB >> 21149477 |
Cristina Müller1, Roger Schibli.
Abstract
The folate receptor (FR) is overexpressed on a variety of tumor types, whereas its distribution in normal tissues and organs is highly limited. Exploration of the utility of the FR revealed its promising potential for targeting with folate-based radiopharmaceuticals. Herein, we report the principle of the FR-targeting strategy and summarize the development of several folic acid radioconjugates useful for SPECT and PET of cancer diseases. The potential applicability of folate radiopharmaceuticals for FR-targeted radionuclide therapy is also discussed.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21149477 DOI： 10.2967/jnumed.110.076018
Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057